{"id":"single-dose-of-hydroxychloroquine","safety":{"commonSideEffects":[{"rate":null,"effect":"Retinopathy"},{"rate":"5–10","effect":"Gastrointestinal disturbance (nausea, diarrhea)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Cardiomyopathy (rare, with long-term use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydroxychloroquine accumulates in lysosomes and endosomes, raising their pH and interfering with antigen presentation and toll-like receptor activation. This suppresses the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-17, making it effective in treating autoimmune and inflammatory conditions. It also has weak anticoagulant properties and may reduce thrombotic events.","oneSentence":"Hydroxychloroquine is an antimalarial and immunomodulatory agent that inhibits toll-like receptor signaling and reduces inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:18.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria"},{"name":"Systemic lupus erythematosus (SLE)"},{"name":"Rheumatoid arthritis"},{"name":"Sjögren's syndrome"}]},"trialDetails":[{"nctId":"NCT04678648","phase":"PHASE1","title":"A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies","status":"RECRUITING","sponsor":"RasCal Therapeutics, Inc.","startDate":"2021-03-03","conditions":"Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer","enrollment":134},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT04937907","phase":"PHASE2","title":"Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)","status":"COMPLETED","sponsor":"Shanghai Children's Hospital","startDate":"2021-09-08","conditions":"Alport Syndrome, X-Linked","enrollment":50},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT07294872","phase":"PHASE1","title":"A Study of TIL in Advanced Solid Tumors (CZ)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2026-05-08","conditions":"Solid Tumor, Adult","enrollment":30},{"nctId":"NCT06828328","phase":"EARLY_PHASE1","title":"A Study of GC203 TIL in PDCA (RJ)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2025-02-10","conditions":"Pancreatic Cancer, Pancratic Ductal Adenocarcinoma, Treatment Side Effects","enrollment":10},{"nctId":"NCT04960072","phase":"EARLY_PHASE1","title":"A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-06-30","conditions":"Gastrointestinal Tumor","enrollment":50},{"nctId":"NCT06488950","phase":"EARLY_PHASE1","title":"A Study of TIL in Advanced Solid Tumors (DFGD)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2023-04-01","conditions":"Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects","enrollment":30},{"nctId":"NCT04943913","phase":"EARLY_PHASE1","title":"Study of GC101 TIL in Brain Glioma (Soochow2)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-05-06","conditions":"Glioma","enrollment":50},{"nctId":"NCT04967833","phase":"EARLY_PHASE1","title":"A Study of GC101 TIL in Advanced Solid Tumors (TR)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-04-22","conditions":"Advanced Solid Tumors","enrollment":20},{"nctId":"NCT05098171","phase":"EARLY_PHASE1","title":"A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-09-26","conditions":"Advanced Gynecologic Tumors, Signal Switch Receptor Modified TIL, Treatment Side Effects","enrollment":50},{"nctId":"NCT05142475","phase":"EARLY_PHASE1","title":"A Study of GC101 TIL in Advanced Breast Cancer (10hospital)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-11-19","conditions":"Breast Cancer, Treatment Side Effects, Advanced Breast Cancer","enrollment":50},{"nctId":"NCT05098197","phase":"EARLY_PHASE1","title":"A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-09-26","conditions":"Advanced Liver Cancers, Tumor Infiltrating Lymphocyte, Treatment Side Effects","enrollment":50},{"nctId":"NCT05098184","phase":"EARLY_PHASE1","title":"A Study of GC101 TIL in Advanced Melanoma (10hospital)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-09-26","conditions":"Advanced Melanoma, Tumor Infiltrating Lymphocyte, Treatment Side Effects","enrollment":50},{"nctId":"NCT05576896","phase":"PHASE2","title":"Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2022-10-10","conditions":"Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV","enrollment":43},{"nctId":"NCT03030118","phase":"PHASE2","title":"Study of Anti-Malarials in Incomplete Lupus Erythematosus","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2017-12-28","conditions":"Systemic Lupus Erythematosus","enrollment":187},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT03377179","phase":"PHASE2","title":"A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2018-03-07","conditions":"Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar","enrollment":65},{"nctId":"NCT06676384","phase":"PHASE4","title":"Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","status":"RECRUITING","sponsor":"Christian Medical College, Vellore, India","startDate":"2025-02-15","conditions":"IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis","enrollment":585},{"nctId":"NCT04379492","phase":"PHASE2","title":"A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19","status":"WITHDRAWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-05-05","conditions":"COVID-19, COVID19, Sars-CoV2","enrollment":""},{"nctId":"NCT06887517","phase":"","title":"Chinese Rheumatism Biobank(CRB)","status":"RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2025-02-10","conditions":"Lupus Erythematosus, Systemic","enrollment":300},{"nctId":"NCT04363827","phase":"PHASE2","title":"Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2020-05-14","conditions":"COVID19, Hydroxychloroquine, Prophylaxis","enrollment":155},{"nctId":"NCT04973566","phase":"PHASE1","title":"A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-31","conditions":"Healthy","enrollment":48},{"nctId":"NCT04386057","phase":"PHASE2","title":"LY3214996 +/- HCQ in Pancreatic Cancer","status":"COMPLETED","sponsor":"Kimberly Perez, MD","startDate":"2020-05-27","conditions":"Pancreatic Cancer, Advanced Cancer","enrollment":52},{"nctId":"NCT05458622","phase":"PHASE3","title":"3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Brest","startDate":"2022-11-29","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":25},{"nctId":"NCT04315948","phase":"PHASE3","title":"Trial of Treatments for COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-03-22","conditions":"Corona Virus Infection","enrollment":1552},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT05087745","phase":"EARLY_PHASE1","title":"A Clinical Study on TIL for the Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-12-10","conditions":"Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects","enrollment":50},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT00579878","phase":"PHASE3","title":"Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-03-27","conditions":"Rheumatoid Arthritis","enrollment":69},{"nctId":"NCT02475915","phase":"PHASE1, PHASE2","title":"Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection","status":"COMPLETED","sponsor":"SEARCH Research Foundation","startDate":"2015-01","conditions":"Acute HIV Infection","enrollment":15},{"nctId":"NCT01649947","phase":"PHASE2","title":"Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2011-12-23","conditions":"Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer","enrollment":32},{"nctId":"NCT04335305","phase":"PHASE2","title":"Checkpoint Blockade in COVID-19 Pandemic","status":"TERMINATED","sponsor":"MedSIR","startDate":"2020-04-09","conditions":"COVID-19, Pneumonia, Viral","enrollment":12},{"nctId":"NCT05302947","phase":"","title":"COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU","status":"COMPLETED","sponsor":"Pirogov Russian National Research Medical University","startDate":"2020-02-01","conditions":"COVID-19, Mild to Moderate","enrollment":154},{"nctId":"NCT04374539","phase":"PHASE2","title":"Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial","status":"TERMINATED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2020-04-29","conditions":"Coronavirus","enrollment":36},{"nctId":"NCT04394182","phase":"NA","title":"Ultra Low Doses of Therapy With Radiation Applicated to COVID-19","status":"SUSPENDED","sponsor":"Fundacion GenesisCare","startDate":"2020-04-21","conditions":"Pneumonia, Viral, Cytokine Storm","enrollment":15},{"nctId":"NCT04275778","phase":"PHASE2","title":"HYDROxychloroquine in Syndrome Primary AntiPhospholipid","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-07-09","conditions":"Antiphospholipid Syndrome in Pregnancy, Anticoagulants","enrollment":110},{"nctId":"NCT05237843","phase":"PHASE1","title":"Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-03-01","conditions":"Recurrent Pregnancy Loss","enrollment":70},{"nctId":"NCT03122431","phase":"PHASE4","title":"Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-06-05","conditions":"Systemic Lupus Erythematosus (SLE), Juvenile SLE, Cutaneous Lupus","enrollment":93},{"nctId":"NCT04697654","phase":"PHASE1","title":"The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2020-10-08","conditions":"COVID-19","enrollment":30},{"nctId":"NCT04358068","phase":"PHASE2","title":"Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-05-13","conditions":"COVID-19, SARS-CoV 2","enrollment":20},{"nctId":"NCT05004753","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects","status":"COMPLETED","sponsor":"Mateon Therapeutics","startDate":"2020-09-30","conditions":"Covid19","enrollment":120},{"nctId":"NCT04347980","phase":"PHASE3","title":"Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19","status":"TERMINATED","sponsor":"Centre Chirurgical Marie Lannelongue","startDate":"2020-04-17","conditions":"Respiratory Distress Syndrome, Adult, COVID-19","enrollment":5},{"nctId":"NCT04380818","phase":"NA","title":"Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19","status":"UNKNOWN","sponsor":"Grupo de Investigación Clínica en Oncología Radioterapia","startDate":"2020-06-05","conditions":"Pneumonia, Viral","enrollment":106},{"nctId":"NCT04475120","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"2020-04-15","conditions":"Covid19","enrollment":92},{"nctId":"NCT02722369","phase":"PHASE2","title":"STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)","status":"TERMINATED","sponsor":"University College, London","startDate":"2017-03-14","conditions":"Small Cell Lung Cancer","enrollment":72},{"nctId":"NCT04351191","phase":"PHASE4","title":"PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds","status":"TERMINATED","sponsor":"Government of Punjab, Specialized Healthcare and Medical Education Department","startDate":"2020-04-15","conditions":"Sars-CoV2, Symptomatic Condition, Covid-19","enrollment":137},{"nctId":"NCT04346667","phase":"PHASE4","title":"Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds","status":"TERMINATED","sponsor":"Government of Punjab, Specialized Healthcare and Medical Education Department","startDate":"2020-04-14","conditions":"SARS-CoV-2, Coronavirus Infection, Asymptomatic Condition","enrollment":125},{"nctId":"NCT04788355","phase":"PHASE3","title":"Prevention of Complications (SARS-CoV-2): Clinical Study","status":"COMPLETED","sponsor":"Universidade do Vale do Sapucai","startDate":"2020-07-01","conditions":"Complication","enrollment":176},{"nctId":"NCT04351724","phase":"PHASE2, PHASE3","title":"Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2020-04-16","conditions":"COVID-19","enrollment":500},{"nctId":"NCT04668469","phase":"NA","title":"Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic","status":"COMPLETED","sponsor":"Benha University","startDate":"2020-06-08","conditions":"Covid19","enrollment":600},{"nctId":"NCT04361461","phase":"PHASE3","title":"Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)","status":"WITHDRAWN","sponsor":"Apsen Farmaceutica S.A.","startDate":"2020-04-30","conditions":"Coronavirus Infections, SARS-CoV 2, SARS (Severe Acute Respiratory Syndrome)","enrollment":""},{"nctId":"NCT04359667","phase":"","title":"Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab","status":"UNKNOWN","sponsor":"University Hospital for Infectious Diseases, Croatia","startDate":"2020-06-16","conditions":"COVID-19, Severe Pneumonia","enrollment":30},{"nctId":"NCT04343092","phase":"PHASE1","title":"Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management","status":"COMPLETED","sponsor":"University of Baghdad","startDate":"2020-04-18","conditions":"COVID 19","enrollment":16},{"nctId":"NCT04446104","phase":"PHASE3","title":"A Preventive Treatment for Migrant Workers at High-risk of COVID-19","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2020-05-13","conditions":"Covid-19","enrollment":4257},{"nctId":"NCT04461353","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Pulmoquine Therapeutics, Inc","startDate":"2020-06-25","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2","enrollment":12},{"nctId":"NCT04400019","phase":"PHASE2, PHASE3","title":"Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)","status":"UNKNOWN","sponsor":"University of Malaga","startDate":"2020-09","conditions":"Sars-CoV2, Coronavirus Infection, Prevention & Control","enrollment":1930},{"nctId":"NCT04361422","phase":"PHASE3","title":"Isotretinoin in Treatment of COVID-19","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-12-01","conditions":"COVID-19","enrollment":300},{"nctId":"NCT04443725","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-07","conditions":"COVID-19","enrollment":100},{"nctId":"NCT04362332","phase":"PHASE4","title":"Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19","status":"TERMINATED","sponsor":"UMC Utrecht","startDate":"2020-04-14","conditions":"COVID-19","enrollment":25},{"nctId":"NCT04434144","phase":"","title":"A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh","status":"COMPLETED","sponsor":"Upazila Health & Family Planning Officer's (UHFPO) Office, Chakoria, Cox's Bazar","startDate":"2020-05-02","conditions":"Ivermectin, Hydroxychloroquine, COVID19","enrollment":116},{"nctId":"NCT04347512","phase":"PHASE3","title":"EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA","status":"WITHDRAWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-06-02","conditions":"Sars-CoV-2, Community-Acquired Pneumonia,COVID-19","enrollment":""},{"nctId":"NCT04323345","phase":"PHASE3","title":"Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus","status":"UNKNOWN","sponsor":"Misr University for Science and Technology","startDate":"2020-04-15","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT04350671","phase":"PHASE4","title":"Interferon Beta 1a in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-15","conditions":"COVID-19","enrollment":40},{"nctId":"NCT04350684","phase":"PHASE4","title":"Umifenovir in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-15","conditions":"COVID-19","enrollment":40},{"nctId":"NCT04328272","phase":"PHASE3","title":"Effectiveness of Hydroxychloroquine in Covid-19 Patients","status":"UNKNOWN","sponsor":"Prof. Dr. Umar Farooq","startDate":"2020-03-28","conditions":"COVID19","enrollment":75},{"nctId":"NCT02644499","phase":"PHASE4","title":"Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2015-12-31","conditions":"Rheumatoid Arthritis","enrollment":186},{"nctId":"NCT02433184","phase":"PHASE4","title":"Very Early Versus Delayed Etanercept in Patients With RA","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":120},{"nctId":"NCT00486603","phase":"PHASE1, PHASE2","title":"Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-10-29","conditions":"Brain and Central Nervous System Tumors","enrollment":92},{"nctId":"NCT02631252","phase":"PHASE1","title":"Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia","status":"TERMINATED","sponsor":"Alison Sehgal, MD, MS","startDate":"2016-08-18","conditions":"Leukemia, Acute Myelogenous","enrollment":1},{"nctId":"NCT00728845","phase":"PHASE1, PHASE2","title":"Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2008-06-16","conditions":"Lung Cancer","enrollment":8},{"nctId":"NCT01634893","phase":"PHASE1","title":"Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2012-06","conditions":"Refractory or Relapsed Solid Tumors","enrollment":18},{"nctId":"NCT01015547","phase":"PHASE3","title":"Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2003-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT00720798","phase":"PHASE3","title":"An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-09","conditions":"Rheumatoid Arthritis","enrollment":2067},{"nctId":"NCT01833845","phase":"PHASE1, PHASE2","title":"Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C","status":"TERMINATED","sponsor":"BioLineRx, Ltd.","startDate":"2013-04","conditions":"Hepatitis C","enrollment":4},{"nctId":"NCT00531817","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Rheumatoid Arthritis","enrollment":619}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Single Dose of Hydroxychloroquine","genericName":"Single Dose of Hydroxychloroquine","companyName":"Shahid Beheshti University of Medical Sciences","companyId":"shahid-beheshti-university-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydroxychloroquine is an antimalarial and immunomodulatory agent that inhibits toll-like receptor signaling and reduces inflammatory cytokine production. Used for Malaria, Systemic lupus erythematosus (SLE), Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}